TY  - JOUR
T1  - VAccination of infants with hpv-77 vaccine
AU  - Pavilanis V, Chagnon A, Davignon L, Joncas J
Y1  - 1969/08/01
N1  - 10.1001/archpedi.1969.02100040249017
JO  - American Journal of Diseases of Children
SP  - 247
EP  - 251
VL  - 118
IS  - 2
N2  - IN 1966, clinical trials demonstrated that a rubella virus modified by 77 passages in African green monkey kidney cultures (GMK) was attenuated for man.1,2 This strain (HPV-77) produced asymptomatic immunizing infections that were not communicable to contacts. The HPV-77 could be recovered from the respiratory secretions of recipients, and the vaccine induced levels of antibodies averaged six-to eightfold lower than in children convalescent from natural rubella. Most clinical trials were conducted in children and adolescents. Extending those experiences, the present report describes our experience with HPV-77 strain administered to infants.Materials and Methods 
    Study Population and Experimental Design.—Infants from 5 to 12 months of age living in a public nursery were chosen to take part in this trial. Before admission to isolation unit each one was screened for susceptibility to rubella. Those having no detectable hemagglutination-inhibiting (HI) antibodies at 1:5 dilution and no neutralizing (NT) antibodies at
SN  - 0002-922X
M3  - doi: 10.1001/archpedi.1969.02100040249017
UR  - http://dx.doi.org/10.1001/archpedi.1969.02100040249017
ER  -